drugset / Trial / NCT07592910
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
Phase 2
Not yet recruiting
60 enrolled
Prostate Cancer Clinical Trials Consortium
Dana-Farber Cancer Institute · collabFred Hutchinson Cancer Center · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.
Timeline
- Start
- 2026-08
- Primary completion
- 2029-05
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Mevrometostat | Small molecule | 875 mg | Oral |